SNPs associated with disease susceptibility often reside in enhancer clusters, or super-enhancers. Constituents of these enhancer clusters cooperate to regulate target genes and often extend beyond the linkage disequilibrium (LD) blocks containing risk SNPs identified in genome-wide association studies (GWAS). We identified 'outside variants', defined as SNPs in weak LD with GWAS risk SNPs that physically interact with risk SNPs as part of a target gene's regulatory circuitry. These outside variants further explain variation in target gene expression beyond that explained by GWAS-associated SNPs. Additionally, the clinical risk associated with GWAS SNPs is considerably modified by the genotype of outside variants. Collectively, these findings suggest a potential model in which outside variants and GWAS SNPs that physically interact in 3D chromatin collude to influence target transcript levels as well as clinical risk. This model offers an additional hypothesis for the source of missing heritability for complex traits.
Transcriptional regulatory elements are hotspots for genetic predisposition to disease. SNPs associated with disease susceptibility by GWAS are heavily enriched in putative cell-type-specific regulatory elements, mostly enhancers, demarcated through ChIP-seq studies of signature histone marks and associated transcription factors [1] [2] [3] [4] [5] [6] . Of the heritability estimates for common disease made by GWAS, variants in regulatory elements are estimated to account for 79% of the variance 7 . Enrichment is particularly pronounced in regions of enhancer clusters, which have been described as superenhancers 8, 9 , stretch enhancers 10 and multiple-enhancer variant (MEV) loci 5 . Enhancer clusters involve multiple, robust, cell-typespecific enhancers arranged in cis and are often located near genes that function to establish and/or maintain cellular identity [8] [9] [10] [11] . At enhancer clusters associated with disease risk, it has been proposed that multiple SNPs distributed across the individual enhancer constituents cooperatively influence enhancer activity and effect expression of the target gene 5, [12] [13] [14] [15] [16] [17] [18] .
Regulatory variants associated with disease susceptibility often influence target transcript levels, and expression quantitative trait locus (eQTL) studies have had great success in identifying functional variants. GWAS variants are enriched for eQTLs [19] [20] [21] , and this enrichment is particularly pronounced among eQTLs in tissues relevant to the pathogenesis of a given disorder 22 . However, thus far, eQTLs have not been identified for the majority of GWAS loci [19] [20] [21] 23, 24 . There are a variety of possible explanations: eQTLs may only be apparent in very specific cell types or conditions, or the effect sizes are small and large samples are therefore required for their detection. An alternative explanation is that physical interactions among enhancer SNPs, dictated by higherorder chromatin folding at enhancer clusters, influence target transcript levels. Indeed, analysis of 3D genomic architecture has demonstrated that multiple enhancers that are all part of a gene's regulatory circuitry can physically interact with one another and collectively engage a target promoter to facilitate transcription 25, 26 . The SNPs within a gene's regulatory circuit could cooperate in various ways to influence target gene expression, including additively 27, 28 , synergistically 29 , conditionally [29] [30] [31] [32] [33] , epistatically or through currently unknown modalities that are dependent on locus and cell context. Regardless of the modality, SNPs within physically interacting enhancers could exert effects on target gene expression that may be missed by traditional eQTL analyses. Furthermore, given that a gene's regulatory circuitry is independent of haplotype block structure, it is possible that SNPs in weak LD with GWAS risk SNPs, but within the same regulatory circuit, participate in the regulation of target gene expression and influence the overall clinical risk of disease.
RESULTS

Regulatory circuitry at GWAS loci extends beyond LD blocks
In comparison to randomly sampled SNPs, SNPs associated with risk for six autoimmune diseases-rheumatoid arthritis, systemic lupus, Crohn's disease, multiple sclerosis, ulcerative colitis and celiac disease-are highly enriched in active gene enhancer elements in B lymphoblasts, as well as B cells and T cells (which share a common regulatory landscape at risk-associated loci) 1, 5 . We identified highconfidence interactions from B-lymphoblast high-resolution Hi-C data that associated putative regulatory elements (demarcated by Modeling disease risk through analysis of physical interactions between genetic variants within chromatin regulatory circuitry VOLUME 48 | NUMBER 11 | NOVEMBER 2016 Nature GeNetics a n a ly s i s monomethylation of histone H3 at lysine 4, H3K4me1) with promoters for 170 GWAS loci. For 78% of these loci, promoters associated with putative regulatory elements containing GWAS-linked SNPs were also associated with regulatory elements that contained outside variants, that is, SNPs in weak LD with the GWAS-linked SNPs (Supplementary Fig. 1a ). An example is shown in Figure 1a , where Hi-C interactions associate multiple sclerosis risk SNP rs9282641 with the CD86 promoter. The CD86 promoter is also physically associated with an additional putative regulatory element that contains variants in weak LD with the GWAS SNP (D′ < 0.5 and r 2 < 0.1). Thus, the regulatory circuitry of CD86 extends beyond the haplotype block from which the GWAS association arose.
Given the limitations of Hi-C resolution, we also employed a computational method, PreSTIGE 5 , to identify the potential gene targets of putative regulatory elements containing risk SNPs at 112 autoimmune disease-associated loci in B lymphoblasts. Consistent with our findings using Hi-C-defined interactions, for 79% of the loci we evaluated, putative regulatory elements containing risk SNPs were predicted to regulate target genes in cooperation with regulatory elements containing outside variants. An example is shown in Figure 1b , where the multiple sclerosis risk SNP rs7191700 is predicted to target SOCS1. SOCS1 is also predicted to be controlled by additional regulatory elements containing outside variants.
Finally, we compared haplotype structure at risk loci to superenhancers-clusters of active gene regulatory elements that are proposed to act cooperatively on target gene expression 8, 9 . We detected outside variants at 49% of risk loci containing super-enhancers. An example is shown in Figure 1c , where a super-enhancer containing a lupus-associated SNP, rs13277113, extends 17 kb beyond the associated block and contains outside variants. Thus, regardless of how regulatory circuitry was defined-by using Hi-C interactions, computationally predicted enhancer-gene interactions or superenhancers-DNA variants that are part of a common regulatory circuitry but are in weak LD with the risk locus were frequently observed ( Supplementary Fig. 1b,c) .
Physical interactions between SNPs influence gene expression
We next sought to determine whether outside variants affect the levels of target gene expression. We used B-lymphoblast transcriptome data along with corresponding SNP genotype data from 373 Europeans 34 . Given that there are diverse modalities by which different enhancers function and that these modalities are locus dependent, we developed a two-tiered eQTL-based approach in which individuals were first stratified on the basis of the genotype of the 'GWAS allele' (GWAS lead SNP and variants in tight LD (logarithm of odds (LOD) > 2 and D′ > 0.6); Online Methods) and were then further subdivided on the basis of the genotype of outside variants (Fig. 2a) . The two-tiered stratification approach is designed to be agnostic to the interaction modality of enhancers within a cluster, be it additive, epistatic, synergistic or a novel, uncharacterized mechanism. The approach evaluates the impact of the outside variant on each GWAS allele genotype (non-risk/nonrisk, non-risk/risk and risk/risk) separately. The approach is designed to capture variants that account for additional variation in gene expression beyond the effect of variants in tight LD (LOD > 2 and D′ > 0.6) with the allele for the GWAS-associated SNP. We started with the multiple sclerosis-associated SYK (spleen tyrosine kinase) locus on chromosome 9. SYK has an important role in ITAM-mediated signaling transduction from B cell receptors to downstream cellular functions 35 . We identified an outside variant (rs3904534) that lies in a putative regulatory element that is computationally predicted to regulate SYK and was determined through Hi-C analysis to be physically associated with the SYK promoter ( Fig. 2b) . There was no significant difference in SYK expression based on the genotype of the risk locus alone ( Fig. 2c , left). When individuals homozygous for the risk allele were further stratified by the genotype of the outside variant, a significant difference in SYK transcript levels was observed ( Fig. 2c, right) .
We expanded our two-tiered eQTL-based strategy to evaluate the impact of outside variants defined by our three methods of determining the chromatin regulatory circuitry for a total of 186 GWAS loci (Online Methods and Supplementary Fig. 2 ). We then compared P values calculated by quantifying the effects of outside variants on target gene expression levels to those from random permutations and found that the outside variant genotype frequently altered transcript levels (Fig. 2d) . Twenty-four to 34% of all GWAS loci evaluated involved at least one outside variant significantly associated with gene expression (Online Methods, Supplementary Fig. 2g and Supplementary Table 1 ). Hereafter, we refer to these as 'functional outside variants' . These estimates were based on two different methods for multiple-test correction: false discovery rate (FDR) and generation of null P-value distributions from permutations for each locus (Online Methods) 36, 37 . Outside variants were identified regardless of the approach used to define regulatory circuitry, and the rates were comparable for all three methods. Sixty-one percent of the functional outside variants were not previously identified as independent eQTLs (Supplementary Fig. 3 ).
Functional outside variants share key features of enhancers
We hypothesized that outside variants alter the effect of GWAS alleles on target transcript levels by altering enhancer function within shared regulatory circuits. Using publicly available data sets from 27-68 B-lymphoblast cell lines, we compared the chromatin features associated with functional outside variants to those of disease-associated variants [38] [39] [40] . Example loci are shown in Figure 3a ; although some between-individual variability was evident, we detected enrichment for DNase I hypersensitivity, H3K4me1 and acetylation of histone H3 at lysine 27 (H3K27ac) across individuals for outside variant rs7158350 and GWAS-linked variant rs9275184. Similar enrichment was observed across all loci with functional outside variants ( Fig. 3b) . Eighty-five percent of functional outside variants were enriched for H3K27ac, H3K4me1 and DNase I hypersensitivity in more than twothirds of all cell lines analyzed.
We also analyzed B-lymphoblast ChIP-seq data sets for >75 unique transcription factors 41 . Both functional outside variants and GWAS-linked variants were bound by transcription factors significantly more often than expected by chance ( Fig. 3c) . Seventy-seven percent of functional outside variants were located within 1 kb of transcription factor binding sites mapped through ChIP-seq studies ( Fig. 3d) . By comparison, 12% of randomly selected SNPs were located within 1 kb of transcription factor binding sites. The transcription factors most frequently bound at outside variants were ones with known roles in mounting immune responses and hematopoiesis, including RUNX3, PU.1 and EBF1 (refs. 42-44) ( Fig. 3e) .
To directly evaluate enhancer activity at outside variants, we cloned eight functional outside variant loci and two control regions into luciferase reporter constructs and evaluated the enhancer function of these regions in B lymphoblasts ( Supplementary Fig. 4 and Supplementary Table 2 ). Seven of eight functional outside variant enhancer loci significantly enhanced luciferase activity in comparison to the two control regions. We evaluated five of these eight loci for differential enhancer activity based on the outside variant genotype; four showed a significant difference in luciferase activity ( Fig. 3f,g) . Altogether, the results suggest that outside variants functionally modify target transcript levels by altering enhancer activity in the B-lymphoblast lineage. a n a ly s i s
Outside variants alter clinical risk to disease
We set out to test whether functional outside variants modify clinical disease risk. We used data generated by the Wellcome Trust Case Control Consortium [45] [46] [47] [48] to evaluate the impact of functional outside variants on clinical risk for multiple sclerosis, Crohn's disease, ulcerative colitis and rheumatoid arthritis. We compared the clinical risk for each GWAS-associated SNP and functional outside variant, independently, to the clinical risk associated with each genotype combination. An example is shown in Figure 4a . We stratified the multiple sclerosis cases and control population on the basis of the where the gene target SOCS1 is predicted to be regulated by enhancers (highlighted in gray) that contain variants linked to GWAS SNP rs7191700 and outside variants. Right, proportion of GWAS loci containing outside variants for PreSTIGE-defined enhancer-gene interactions (n = 156 total GWAS loci). (c) Example of a super-enhancer lupus risk locus that contains both variants linked to GWAS SNP rs13277113 and outside variants. Right, proportion of GWAS loci containing outside variants for super-enhancer loci (n = 159 total GWAS loci). a n a ly s i s genotype of the GWAS-associated SNP rs13333054 and found individuals homozygous for the risk SNP to have an odds ratio of 1.18. We also stratified individuals solely by the genotype of the outside variant rs12445129 and found an odds ratio of 1.12 for the TT genotype. When we determined the odds ratio on the basis of the genotype of both variants, we found an increase in clinical risk to an odds ratio of 1.77 for individuals homozygous for the GWAS risk SNP and homozygous for the T allele of the outside variant. Thus, the genotype of the outside variant alters the clinical risk associated with the locus. Outside variant rs2760912 was found to significantly alter the impact of multiple sclerosis GWAS-associated SNP rs806321 on expression of the lymphocytic leukemia-associated RNA gene DLEU1. Inheriting the G allele of the outside variant was associated with increased transcript levels (Fig. 4b, top) . Likewise, individuals homozygous for the risk SNP and G allele of the outside variant had a notable increase in risk to disease (Fig. 4b, bottom ). Outside variant rs1800872 was found to significantly alter the impact of ulcerative colitis GWAS-associated SNP rs3024505 on IL19 target transcript levels. In this instance, a decrease in expression of IL19 was correlated with an increase in clinical risk ( Fig. 4c) . To evaluate the significance of the impact of the outside variant on clinical risk, we performed permutation analysis in which individuals of each genotype for the GWAS-associated SNP (risk/risk, risk/non-risk and non-risk/ non-risk) were randomly assigned an outside variant genotype while maintaining the outside variant's minor allele frequency. Thus, the contribution of the GWAS SNP to risk was preserved to evaluate the ability of the outside variant to alter clinical risk ( Fig. 4b-d and Online Methods). Using this metric, outside variants rs12445129, rs2760912 and rs1800872 ( Fig. 4a-c) were found to significantly alter clinical risk (P < 0.01). We expanded these analyses to include all functional outside variants detected across all four traits. The impact of functional outside variants on clinical risk for each significant GWAS-associated locus (P < 0.01) is shown in Figure 4d . In total, 73.5% of the GWAS loci evaluated were associated with a functional outside variant that significantly altered the clinical risk associated with the locus (P < 0.05; 55% at P < 0.01) ( Fig. 4e) .
Although the majority of functional outside variants were observed to alter clinical risk, these outside variants were not previously associated with the disorders by conventional GWAS. To evaluate why, we determined the impact of these variants on risk independently of the genotype for the GWAS-associated SNP. For less than one-quarter of the GWAS loci associated with one or more functional outside variants, at least one outside variant reached genome-wide significant association with risk when evaluated independently. The majority of these variants were from imputation analysis (Online Methods) and were therefore not evaluated by the previous GWAS. Another possibility is that outside variants are just below genome-wide significance and would be associated with clinical risk in larger cohorts. Of the GWAS loci, 21.4% were associated with a functional outside variant that independently reached intermediate association with risk Observed (-log P value) a n a ly s i s (1 × 10 −3 ≥ P > 1 × 10 −8 ). Thus, for many of these GWAS loci (57%), the impact of the functional outside variant on risk seems to be contingent on the genotype of the GWAS locus.
Outside variants may explain additional heritability
We sought to evaluate the overall impact of functional outside variants on disease heritability. The colocalization of disease susceptibility loci across autoimmune diseases 49, 50 suggests that these disorders may involve disruption of common pathways. Thus, we used functional outside variant loci associated with risk for all six autoimmune disorders to estimate genetic relationship matrices (GRMs) and narrow-sense heritability (h g 2 ) for each trait (Online Methods).
We compared the heritability explained by the GWAS lead SNPs for all functional outside variant loci to the heritability explained when rs1077667  rs390821  rs3024493  rs4072226  rs874040  rs10003949  rs6498169  rs9302456  rs4953911  rs1257204  rs17445836  rs731707  rs12456021  rs12963422  rs7238078  rs8090585  rs2300747  rs850609  rs3024505  rs1800872  rs7923837  rs11187083  rs2283792  rs17759598  rs13333054  rs12445129  rs11203203  rs7282464  rs11150589  rs9934579  rs806321  rs2760912  rs11755724  rs1285873  rs1335532  rs850609  rs354033  rs11763561  rs290986  rs290990  rs9596270  rs2760912  rs12025416  rs850609  rs3024505  rs12044804  rs16940202  rs7199472  rs11175593  rs1873612  rs630923 a n a ly s i s the GWAS lead SNPs and functional outside variants were jointly modeled. Functional outside variants increased the total heritability explained by 2.6-fold for rheumatoid arthritis (P < 0.03), 5-fold for ulcerative colitis (P < 1 × 10 −4 ) and 3.8-fold for multiple sclerosis (P < 1 × 10 −30 ) (Fig. 4f) . Functional outside variants also increased h g 2 (the fraction of phenotypic variance explained by SNPs) significantly more than is expected on the basis of the genomic coverage of functional outside variants. Gusev et al. previously demonstrated that inclusion of local variants increases the total heritability attributed to GWAS loci 51 . Functional outside variants explained significantly more heritability than local controls for both ulcerative colitis and multiple sclerosis (ulcerative colitis, P < 0.03; multiple sclerosis, P < 1 × 10 −30 ; Supplementary Fig. 5) . Thus, functional outside variants are a distinct set of local variants that can account for a substantial increase in total heritability explained.
Evaluation of third variants at outside variant loci
Our results suggest that multiple SNPs within the same regulatory circuit may cooperate to influence gene expression and clinical risk.
Alternatively, a single variant that is partially linked to both the GWASassociated and outside variants may be responsible for the observed effects. For example, SNPs recently identified as interacting and in statistical epistasis with one another were subsequently shown also to be in low LD with a single 'third SNP' (refs. 52,53) . The presence of the third SNP calls into question whether the two interacting SNPs actually drive the effect on expression; instead, the effect may be driven solely by the single third SNP that is in LD with each of the interacting SNPs. We systematically looked for evidence of third SNPs at all loci containing functional outside variants. We first curated a list of candidate third SNPs by selecting all known common SNPs within 500 kb of gene targets with functional outside variants. A total of 158,083 SNPs were identified, averaging 4,863 SNPs per gene ( Supplementary Table 3 ). At every locus, we identified a third variant that at least nominally correlated with gene expression. However, the third SNP was often insufficient to account fully for the effect of the outside variant. For example, after segregating individuals with the same genotype for the third variant, the outside variant often accounted for additional variation in gene expression ( Supplementary Figs. 6 and 7) . We further tested whether any of the third variants could account for the effects on both gene expression and clinical risk. We found that the third SNP accounted for these effects for ~13% (7/53) of the genes evaluated. These loci were associated with risk of disease at a genome-wide level of P < 1 × 10 −8 .
Because imputation can sometimes result in underestimation of effect sizes 54, 55 , we also performed the analysis at less stringent significance thresholds. At an uncorrected P-value threshold of P < 0.001, for 57% of outside variant gene targets, we did not identify a common SNP that could account for the effects of outside variants on both gene expression and risk. We also determined that the majority of third SNPs were not contained within open chromatin, nor did they overlap with either of the two canonical enhancer histone marks H3K4me1 or H3K27ac (Supplementary Fig. 8) . On the basis of this analysis, outside variants seem to account for effects on both clinical risk and gene expression more often than any single third variant alone. We note, however, that our analysis does not consider potential third variants that could be located >500 kb from the gene target, are poorly represented by the GWAS panel or may have low minor allele frequency.
DISCUSSION
Some GWAS loci harbor a single causal variant that lies in an enhancer and influences spatiotemporal expression of the target gene [56] [57] [58] [59] . However, other GWAS loci-particularly those with enhancer clusters, or super-enhancers-contain multiple functional enhancer variants in LD that collude to influence target gene expression 5, [12] [13] [14] [15] [16] 18, 60, 61 . Here we demonstrate that the individual constituents of enhancer clusters physically interact and are rarely in LD, prompting the hypothesis that LD analysis alone might not be the best way to identify variants that comprehensively explain disease heritability. We tested this hypothesis by integrating autoimmune disease-associated GWAS SNPs with epigenomic maps of regulatory elements, Hi-C chromatin interaction maps and transcriptomic data sets. We identified numerous functional outside variants in weak LD with GWAS loci but that lie within constituent enhancers of shared target genes and influence both target gene expression and clinical risk of disease. The outside variants may as much as triple the total heritability explained, although one limitation is that these estimates are based on the widely used additive model of heritability and therefore may not account for the contribution of epistatic effects. Our findings emphasize the importance of chromatin state and a gene's regulatory circuitry as a key determinant of heritable disease risk. On the basis of these findings, it is tempting to speculate that outside variants explain some of the missing heritability for other GWAS traits besides the autoimmune disorders studied here and that new disease risk associations can be identified by studying SNPs that interact in 3D chromatin to regulate gene expression.
URLs. PreSTIGE algorithm http://genetics.case.edu/prestige; PreSTIGE database http://prestige.case.edu/; National Human Genome Research Institute (NHGRI) GWAS catalog (accessed 10 January 2014), https://www.genome.gov/26525384/catalog-of-publishedgenomewide-association-studies/.
METhODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METhODS
Definition of chromatin regulatory circuits. We used high-depth GM12878 Hi-C data sets (1.2 billion paired-end reads 62 ) to define Hi-C chromatin interactions. Both sequences from paired-end reads were aligned to hg18 independently using bowtie2 (ref. 63 ). The Hi-C analysis package available through HOMER 64 was used to define significant interactions between genomic loci at 10-kb resolution (P < 2.5 × 10 −5 ). H3K4me1-enriched loci were called using BWA 65 and MACS 66 . We identified Hi-C significant interactions for which there was a transcription start site in one locus that was paired to an H3K4me1 ChIP peak in the other. These pairs were used to define the list of H3K4me1 putative enhancer sites that were associated with the same gene target, i.e., to define the chromatin regulatory circuitry of each locus. Computational prediction of enhancer-gene interactions was also used to define chromatin regulatory circuitry. The PreSTIGE (Predicting Specific Tissue Interactions of Genes and Enhancers) algorithm was used to predict enhancer-gene interactions from GM12878 H3K4me1 ChIP-seq and RNA-seq data as previously described 5 . Briefly, PreSTIGE uses a comparative analysis across multiple tissue types to identify enhancers and gene with concordant cell type specificity within a defined linear domain. Super-enhancers previously defined for GM12878 (refs. 8,9) were also used to define chromatin regulatory circuits. All genes within 100 kb of super-enhancers were evaluated in transcriptional analysis.
Definition of outside variants for transcriptional analysis. GWAS variants associated with multiple sclerosis, celiac disease, Crohn's disease, ulcerative colitis, systemic lupus and rheumatoid arthritis in European populations were downloaded from the National Human Genome Research Institute (NHGRI) catalog of GWAS variants. SNPs in tight LD (LOD > 2 and D′ > 0.6) with GWAS SNPs were defined as linked variants. All GWAS SNPs in tight LD with variants found in protein-coding regions were excluded from all subsequent analyses. Noncoding linked variants were compared to chromatin regulatory circuits (defined above) to identify potential gene targets. All common variants within putative enhancers associated with these gene targets were identified. Variants in tight LD with GWAS SNPs were removed (LOD > 2 and D′ > 0.6) to create a list of candidate outside variants. This list was further pruned by removing all candidate variants that were in tight LD (LOD > 2 and D′ > 0.6) with a third variant that was in tight LD (LOD > 2 and D′ > 0.6) with a GWAS SNP. Thus, there was no overlap between the variants in tight LD with the GWAS risk SNPs and those in tight LD with the putative outside variants (diagram in Supplementary Fig. 2a ). The resultant r 2 , D′ and LOD scores for GWAS and outside variant pairs are described in Supplementary  Figure 2c- Fig. 2) to ensure sufficient power.
Impact of outside variants on target transcript levels.
We obtained publicly available genotypes and RNA-seq data from the B lymphoblasts of 373 European individuals 34 . The reported PEER-normalized expression was used to control for technical variance 34 . We first stratified this panel by the genotype of the GWAS allele (lead SNPs + all linked variants) and then divided each GWAS genotype subgroup by the genotype of the outside variant. Transcript levels of gene targets defined by regulatory circuitry analysis were compared (Wilcoxon test) to determine the impact of the outside variant genotype on expression for each GWAS genotype (risk/risk, risk/non-risk, nonrisk/non-risk). The P values generated were pruned so that outside variants that stratified individuals into the same groups were only represented once in the construction of quantile-quantile plots.
Definition of functional outside variants. Permutation analysis was used to define outside variants that significantly influence the effect of GWAS alleles on target transcript levels. Permutations randomly associated an individual's genotypes to a different individual's RNA-seq profile. Thus, the LD and allele frequencies were maintained, but association with gene expression was randomized (5,000 permutations). Multiple-test correction was performed with two methodologies. The number of significant tests for each permutation was compared to the number of significant tests in the non-randomized data to define the FDR for each P-value threshold. Alternatively, the lowest P value generated for each GWAS allele (risk/risk, non-risk/risk and non-risk/non-risk) was identified for all GWAS loci. The lowest P values from each of the 5,000 permutations were used to generate an expected distribution for each locus and GWAS allele. P values below the 1st percentile of the expected distribution for the locus were defined as significant (referred to as permutation P < 0.01). 'Functional outside variants' include variants that were determined as significant by the FDR methodology (q < 0.10) or permutation methodology (P < 0.01).
Chromatin state of outside and linked variants. H3K4me1 and H3K27ac B-lymphoblast ChIP-seq and B-lymphoblast DNase I hypersensitivity data were aligned to hg18 using BWA 65 . RPKM values were calculated for the 1-kb region surrounding functional outside variants and GWAS-linked variants, and results were quantile normalized across individuals for each mark.
Luciferase reporter assays. The GM11993 and GM12005 B-lymphoblast cell lines, mycoplasma negative, were obtained from the Coriell Institute Biorepository. Eight functional outside variant loci (~1-2 kb; Supplementary  Table 2 ) were cloned from B-lymphoblast cell lines that were heterozygous for the outside variant allele of interest into a luciferase reporter construct (pGL4 from Promega) in which expression of the luciferase gene was driven by the ubiquitous mouse Sox9 promoter. Sanger sequencing was used to identify the genotype of the outside variant allele in each clone (Supplementary Fig. 4) . Two control loci, ~1-to 2-kb regions with no expected enhancer activity in B lymphoblasts, were also cloned into the same construct to generate size-matched constructs to control for basal promoter activity. Reporter constructs were transfected into the B-lymphoblast cell line GM12005 using transfection reagent DMRIE-C (Life Technologies). As an internal control, a Renilla luciferase plasmid (pRL-SV40 from Promega) was cotransfected. After 5 h, transfection reagents were replaced with fresh medium. Twenty-four hours after transfection, cells were collected and luciferase reporter levels were compared to Renilla luciferase reporter activity using the Dual-Luciferase Reporter Assay System (Promega).
Odds ratio analysis. Primary GWAS data were obtained from the Wellcome Trust Case Control Consortium for multiple sclerosis (9,772 cases, 2,679 controls), Crohn's disease (1,753 cases, 1,461 controls), ulcerative colitis (2,366 cases, 2,679 controls) and rheumatoid arthritis (1,865 cases, 1,461 controls). Quality control and filtering of SNPs and individuals was performed as previously described [45] [46] [47] [48] . Imputation analysis was performed for all functional outside variant loci associated with these disorders using IMPUTE2 (ref. 67 ) and an integrated reference panel from the 1000 Genomes Project (Phase 1) 68 . Imputation output was filtered to include only genotypes with a probability greater than 0.90, while the remaining two genotypes had probabilities less than 0.3. Odds ratios were calculated for individuals who were stratified by the lead SNP genotype, by the outside variant genotype or by the genotype of both variants. To determine which outside variants significantly altered clinical risk, permutation analysis was used. Permutations were performed such that individuals (cases and controls) of each GWAS allele genotype (risk/risk, risk/non-risk and non-risk/non-risk) were randomly assigned an outside variant genotype while maintaining the allele frequency of the outside variant. The distributions of the resulting odds ratios were then used to define a P value for each odds ratio.
Narrow-sense heritability. GWAS lead SNPs associated with functional outside variants for all six autoimmune traits were used to determine GRMs using GCTA. GCTA restricted maximum-likelihood analysis 69, 70 was then used to determine the proportion of phenotypic variance explained by each SNP subset. h g 2 estimates are reported on a liability scale that estimates European disease prevalence of 0.25% for Crohn's disease, 0.5% for rheumatoid arthritis, 0.28% for ulcerative colitis and 0.13% for multiple sclerosis. We performed two-sample z tests to compare h g 2 estimates from jointly modeling GWAS lead SNPs only to h g 2 estimates from jointly modeling GWAS lead SNPs and functional outside variants. We also calculated the null expected h g 2 on the basis of the fraction of the genome represented by the inclusion of outside variants in the heritability estimates. As previously described 51 
, where x is the fraction of the genome covered by the outside variants. z tests were also performed to compare h g 2 estimates from jointly modeling GWAS lead SNPs and functional outside variants to the null expected heritability estimates.
To investigate whether the increase in heritability was specific to outside variants, we compared outside variants to 'local controls' . Local control variants were defined for each GWAS locus by three requirements. Control variants (i) were within 200 kb of a GWAS lead SNP, (ii) did not lie within the regulatory circuitry defined using any of the three methods (see above) and (iii) had r 2 < 0.3 with all variants in tight LD (LOD > 2, D′ > 0.6) with GWAS SNPs or outside variants. Given the proximity of these controls, many are in tight LD with one another. To compare these controls to outside variants, we employed LD pruning. From the list of potential control SNPs, we removed the SNP with the most LD partners (r 2 > 0.3) one at a time, until no SNP pairs with r 2 > 0.3 remained. We pruned the outside variant list by the same method. We selected 1,000 random subsets of controls such that the number of controls per locus was proportionate to the number of functional outside variants for that locus. We compared the heritability distribution generated from 1,000 random sets and found that both ulcerative colitis and multiple sclerosis outside variants explain significantly more heritability than the local controls (UC, P = 0.004; MS, P < 0.001).
Analysis of the third-variant hypothesis.
We identified all known common SNPs within 500 kb of gene targets with functional outside variants. Individuals were stratified on the basis of the genotype of third SNPs, and expression levels were compared by Mann-Whitney Wilcoxon test. All genotypes present in >1% of the 373-individual panel were assessed. A total of 158,083 SNPs were evaluated, averaging 4,863 SNPs per gene ( Supplementary  Table 3 ). In Supplementary Figures 6 and 7 , we present three different P-value thresholds for evaluating the impact of the third variant on expression. These threshold include (i) multiple-test correction for the total number of Mann-Whitney Wilcoxon tests performed for the analysis (P < 7.5 × 10 −8 ), (ii) multiple-test correction for the number of tests performed for the given gene (P-value threshold varies per gene, corrected P < 0.05) and (iii) multipletest correction for ten tests (P < 5 × 10 −3 ) used to demonstrate loci with third variants that have modest effects.
We next asked whether the third variant is sufficient to explain the observed effect of the outside variants and GWAS allele. To evaluate this, we applied our two-tiered approach and stratified first by the genotype of each third variant. We then asked, given the effect of the third variant, whether the outside variant or GWAS allele could explain additional variation in gene expression ( Supplementary Fig. 6 ). If the third SNP was sufficient to explain the observed effect, further stratification of individuals with the same third-SNP genotype would not distinguish cohorts with significantly different transcript levels. We applied this approach to all third SNPs that achieved each of the three thresholds of significance. The number of genes for which the outside variant or GWAS allele could explain more variance for every significant third SNP was counted (i.e., if the outside variant or GWAS allele could not explain additional variance for all third SNPs, then that locus was considered to be potentially explained by the third SNP and this SNP was carried through to the evaluation of clinical risk).
We next assessed whether the remaining third SNPs were associated with clinical risk. To test this, we took all third SNPs that correlated with expression (at the three significance thresholds) where the outside variant or GWAS allele could not account for additional variation and quantified their effect on clinical risk. For this analysis, we evaluated loci associated with risk to four traits-multiple sclerosis, ulcerative colitis, rheumatoid arthritis and Crohn's disease. Approximately two-thirds of the potential third SNPs were imputed in the respective study. For the two most stringent P-value thresholds, at least one third SNP was represented on the appropriate GWAS panel for each gene. For one outside variant locus associated with rheumatoid arthritis (gene target FLVCR2), three third SNPs that had nominal association with an effect on expression (P < 5 × 10 −3 , uncorrected) were detected. None of these third SNPs were successfully imputed in the rheumatoid arthritis GWAS panel. This gene was excluded from the analysis (Supplementary Figs. 6 and 7, bottom row) .
We also compared third variants to DNase I hypersensitivity, H3K4me1 and H3K27ac profiles for B lymphoblasts (GM12878). We evaluated all third variants that had the potential to explain the effect of outside variants on expression ( Supplementary Figs. 6 and 7 , third arrow) and quantified the proportion that overlapped with regions significantly enriched for each marker (called peaks) of active chromatin (Supplementary Fig. 8 ).
